Evaluation of Antidepressive-like Behaviours and Oxidative Stress Parameters in Mice Receiving Imipramine-Zinc Complex Compound.
antidepressant-like activity
environmental stress
glutathione peroxidase
glutathione reductase
imipramine-zinc complex
mice
oxidative stress
total antioxidant status
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
received:
12
08
2023
revised:
12
09
2023
accepted:
12
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
The study aimed to evaluate the antidepressant-like effects of an imipramine-zinc (IMI-Zn) complex compound on mice and assess the level of oxidative stress parameters. The research also investigated whether the IMI-Zn complex showed superior antidepressant activity compared to individual treatments of both compounds at effective doses and their joint administration at subtherapeutic doses. The study was conducted on mice. Forced swim (FST), tail suspension (TST), and locomotor activity tests were used for behavioral studies. The results demonstrated the IMI-Zn complex's dose-dependent antidepressant potential when orally administered to mice. Its efficacy was similar to the separate administration of therapeutic doses of imipramine (IMI) and zinc (Zn) and their joint administration at subtherapeutic doses. Moreover, subjecting mice to acute stress did not significantly affect the activity of on glutathione peroxidase (GPX), glutathione reductase (GR), and total antioxidant status (TAS), possibly due to the short exposure time to the stress stimulus. By developing the IMI-Zn complex, it might be possible to simplify the treatment approach, potentially improving patient compliance by combining the therapeutic effects of both IMI and Zn within a single compound, thus addressing one of the contributing factors to non-compliance in depression therapy. The IMI-Zn complex could be a valuable strategy to optimize therapeutic outcomes and balance efficacy and tolerability.
Identifiants
pubmed: 37762458
pii: ijms241814157
doi: 10.3390/ijms241814157
pmc: PMC10531591
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical University of Lublin, Poland
ID : Statutory Activity with grant numbers DS48 and DS56
Organisme : Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland
ID : Statutory Activity
Références
Metab Brain Dis. 2010 Jun;25(2):125-33
pubmed: 20455016
JAMA Psychiatry. 2020 Dec 1;77(12):1286-1295
pubmed: 32725180
Pharmacotherapy. 2015 Apr;35(4):433-49
pubmed: 25884531
Psychopharmacology (Berl). 1985;85(3):367-70
pubmed: 3923523
BMC Med. 2012 Jun 29;10:66
pubmed: 22747645
Neuropsychopharmacology. 2012 Jan;37(1):117-36
pubmed: 21976044
Pharmacol Rep. 2008 Sep-Oct;60(5):588-9
pubmed: 19066406
Pol J Pharmacol. 2003 Nov-Dec;55(6):1143-7
pubmed: 14730113
Int J Mol Sci. 2021 Nov 29;22(23):
pubmed: 34884712
J Clin Psychiatry. 2008 Dec;69(12):1928-36
pubmed: 19192475
Nutrients. 2020 Aug 20;12(9):
pubmed: 32825449
Nutr Neurosci. 2014 Feb;17(2):65-71
pubmed: 23602205
Acta Psychiatr Scand Suppl. 2005;(428):25-31, 36
pubmed: 16307617
Acta Psychiatr Scand. 2022 Jul;146(1):85-97
pubmed: 35435249
Behav Brain Res. 2021 May 7;405:113185
pubmed: 33617903
Pharmacol Rep. 2014 Aug;66(4):534-44
pubmed: 24948052
PLoS One. 2013 Dec 19;8(12):e82793
pubmed: 24367556
Nature. 2008 Oct 16;455(7215):894-902
pubmed: 18923511
CNS Neurol Disord Drug Targets. 2017;16(7):837-845
pubmed: 27748185
Arch Med Sci. 2015 Dec 10;11(6):1164-78
pubmed: 26788077
Andrologia. 2022 Oct;54(9):e14508
pubmed: 35842931
Brain Res Rev. 2009 Oct;61(2):105-23
pubmed: 19481572
Nat Rev Neurosci. 2005 Jun;6(6):449-62
pubmed: 15891778
Drugs. 2014 Jun;74(8):855-62
pubmed: 24825489
Neurotox Res. 2016 Jan;29(1):143-54
pubmed: 26581375
Molecules. 2019 Apr 22;24(8):
pubmed: 31013638
Biol Psychiatry. 2013 Dec 15;74(12):872-8
pubmed: 23806573
Biomedicines. 2023 Feb 16;11(2):
pubmed: 36831119
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1913-20
pubmed: 18824054
JPEN J Parenter Enteral Nutr. 2008 Sep-Oct;32(5):509-19
pubmed: 18669902
J Clin Psychiatry. 2015 Dec;76(12):1658-67
pubmed: 26579881
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):676-92
pubmed: 20471444
Nutr Neurosci. 2015 May;18(4):162-8
pubmed: 24621065
Magnes Res. 2016 Mar 1;29(3):112-119
pubmed: 27910808
Dialogues Clin Neurosci. 2006;8(2):191-206
pubmed: 16889105
Mol Cell Biochem. 2010 Dec;345(1-2):91-104
pubmed: 20730621
Physiol Behav. 2008 Oct 20;95(3):365-9
pubmed: 18655800
Curr Neuropharmacol. 2021;19(11):2012-2019
pubmed: 33632103
J Gerontol B Psychol Sci Soc Sci. 2011 Jul;66 Suppl 1:i71-81
pubmed: 21743054
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Depress Anxiety. 2013 Jun;30(6):515-27
pubmed: 23468126
J Trace Elem Med Biol. 2021 Jul;66:126753
pubmed: 33831797
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:125-30
pubmed: 23419244
Metab Brain Dis. 2017 Feb;32(1):97-103
pubmed: 27502410
Oxid Med Cell Longev. 2010 Sep-Oct;3(5):325-31
pubmed: 21150338
Nature. 1977 Apr 21;266(5604):730-2
pubmed: 559941
Toxicol Appl Pharmacol. 2019 Oct 1;380:114689
pubmed: 31344373
J Neurosci Res. 2007 Feb 15;85(3):525-35
pubmed: 17149751
Psychiatr Pol. 2018 Jun 30;52(3):449-457
pubmed: 30218561
J Trace Elem Med Biol. 2012 Jun;26(2-3):80-4
pubmed: 22560194
Indian J Physiol Pharmacol. 1999 Jan;43(1):53-9
pubmed: 27093736
Eur J Pharmacol. 2010 Dec 1;648(1-3):117-26
pubmed: 20826148
Am J Psychiatry. 2011 Jul;168(7):689-701
pubmed: 21536692
Curr Res Neurobiol. 2021 May 23;2:100013
pubmed: 36246514
J Vis Exp. 2012 Jan 29;(59):e3638
pubmed: 22314943
J Neural Transm (Vienna). 2008 Dec;115(12):1621-8
pubmed: 18766297
Mol Nutr Food Res. 2017 Aug;61(8):
pubmed: 28054436
Pharmacol Rep. 2005 Nov-Dec;57(6):713-8
pubmed: 16382189
Pol J Pharmacol. 2000 Sep-Oct;52(5):403-6
pubmed: 11334234
J Affect Disord. 2009 Nov;118(1-3):187-95
pubmed: 19278731
Neuropsychopharmacology. 2018 Jun;43(7):1557-1564
pubmed: 29453441
Science. 2012 Oct 5;338(6103):68-72
pubmed: 23042884
Pharmacol Rep. 2015 Jun;67(3):659-62
pubmed: 25933983
Magnes Res. 2018 Aug 1;31(3):78-89
pubmed: 30714573
Sci Rep. 2022 Jun 2;12(1):9224
pubmed: 35654971
Am J Psychiatry. 2010 Aug;167(8):942-8
pubmed: 20595412
Antioxidants (Basel). 2017 Mar 29;6(2):
pubmed: 28353636
J Endocrinol Invest. 2021 Nov;44(11):2341-2347
pubmed: 34129186
CNS Drugs. 2011 Feb;25(2):109-27
pubmed: 21254788
Neuropsychiatr Dis Treat. 2007 Dec;3(6):855-67
pubmed: 19300621
J Clin Psychopharmacol. 2023 May-Jun 01;43(3):273-277
pubmed: 37039705
Pol J Pharmacol. 2002 Nov-Dec;54(6):681-5
pubmed: 12866724
Biochem Biophys Res Commun. 2019 Oct 15;518(2):337-343
pubmed: 31420165
Pharmacopsychiatry. 1994 Nov;27(6):215-23
pubmed: 7870742
Eur Neuropsychopharmacol. 2008 Feb;18(2):122-7
pubmed: 17719752
J Clin Psychiatry. 1998;59 Suppl 5:32-9; discussion 40-1
pubmed: 9635546
Ther Clin Risk Manag. 2008 Feb;4(1):269-86
pubmed: 18728716
Iran J Psychiatry. 2013 Jun;8(2):73-9
pubmed: 24130605
Pharmacol Rep. 2017 Jun;69(3):456-461
pubmed: 28319749
Neurochem Int. 2009 May-Jun;54(5-6):358-62
pubmed: 19171172
J Affect Disord. 2014 Jan;152-154:19-27
pubmed: 24215896
Pharmacol Rep. 2013;65(6):1535-44
pubmed: 24553002
Curr Top Behav Neurosci. 2011;7:121-47
pubmed: 21225412
Front Nutr. 2014 Sep 01;1:14
pubmed: 25988117
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
J Psychiatr Res. 2022 Jun;150:202-213
pubmed: 35397333